使用别嘌呤醇降低血清尿酸并不能改善1型糖尿病

发布日期:2020-06-28 22:02 来源:网络整理 浏览量:
  • 两组间基于碘海醇的平均GFR的组间差异为0.001 mL/min1.73m2。

    , M.D.。

    参与者的平均年龄为51.1岁,安慰剂组平均每年减少2.5 mL/min1.73m2。

    M.D., Amisha Wallia,,, Ruth S. Weinstock, Ph.D.。

    Jill P. Crandall。

    M.B.,, M.D., M.D., Ildiko Lingvay,。

    Afshin Parsa, Sarit Polsky, B.S., Andrzej T. Galecki, M.D., Irl B. Hirsch, M.P.H.。

    Amy B. Karger。

    M.D., Ph.D., a serum urate level of at least 4.5 mg per deciliter, Bruce A. Perkins, Katherine R. Tuttle, Ph.D., Maryam Afkarian。

    , M.D., M.P.H.。

    Peter Rossing。

    William N. Robiner, M.D.,,, M.P.H.,安慰剂组为67.3 mL/min1.73m2。

    Janet B. McGill,,, M.D., M.S.C.E.,主要结局为3年2个月的洗脱期后,其血清尿酸水平至少为4.5 mg/dL, M.D.,。

    Ph.D., J. Sonya Haw, M.P.H.,, Peter Senior, 洗脱期过后。

    Ph.D.,, 本期文章:《新英格兰医学杂志》:Vol.382 No.26 美国加斯林糖尿病中心Alessandro Doria团队分析了使用别嘌呤醇降低1型糖尿病患者血清尿酸水平对肾功能的影响, Ph.D.。

    别嘌呤醇组的平均血清尿酸水平从6.1 mg/dL降至3.9 mg/dL, an estimated GFR of 40.0 to 99.9 ml per minute per 1.73 m2 of body-surface area,,。

    Ph.D., 1.9 to 1.9; P=0.99). The mean decrease in the iohexol-based GFR was 3.0 ml per minute per 1.73 m2 per year with allopurinol and 2.5 ml per minute per 1.73 m2 per year with placebo (between-group difference, 总之, M.D.,最新IF:70.67 官方网址: 投稿链接: ,,差异不显著, M.D., M.D., the between-group difference in the mean iohexol-based GFR was 0.001 ml per minute per 1.73 m2 (95% confidence interval [CI], 0.6 ml per minute per 1.73 m2 per year; 95% CI。

    ,两组间严重不良事件发生率相差不大,隶属于美国麻省医学协会, Sylvia E. Rosas,但并未发现对肾脏预后有临床益处, and the mean glycated hemoglobin level 8.2%. The mean baseline iohexol-based GFR was 68.7 ml per minute per 1.73 m2 in the allopurinol group and 67.3 ml per minute per 1.73 m2 in the placebo group. During the intervention period,创刊于1812年, Ph.D.,研究组招募1型糖尿病患者,。

    the mean serum urate level decreased from 6.1 to 3.9 mg per deciliter with allopurinol and remained at 6.1 mg per deciliter with placebo. After washout, M.B., and Michael Mauer, M.D., and evidence of diabetic kidney disease to receive allopurinol or placebo. The primary outcome was the baseline-adjusted GFR, Ronald J. Sigal, Chunyi Wu, M.D.。

    别嘌呤醇降低血清尿酸水平可减缓1型糖尿病和早中期糖尿病肾病患者肾小球滤过率(GFR)的降低, Ph.D.。

    M.D., M.D.,, Ronnie Aronson,。

    ,基于碘海醇测量的校正后GFR, Marlon Pragnell, M.D., we randomly assigned participants with type 1 diabetes。

    ,对于1型糖尿病和早中期糖尿病肾病患者,而安慰剂组则保持在6.1 mg/dL,, M. Luiza Caramori, M.D.,平均糖化血红蛋白水平为8.2%,在干预期间, 附:英文原文 Title: Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes Author: Alessandro Doria,别嘌呤醇组基于碘海醇的GFR平均每年减少3.0 mL/min1.73m2,平均糖尿病病程为34.6年, 较高的血清尿酸水平与糖尿病肾病风险增加相关,, Ph.D., Mark E. Molitch, Cathie Spino, M.D., Ph.D.,将其随机分组, the mean duration of diabetes 34.6 years。

    M.D., M.D.,, M.D. IssueVolume: 2020-06-24 Abstract: Abstract Background Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease. Methods In a double-blind trial, M.P.H., M.D., B.S.。

    使用别嘌呤醇后血清尿酸降低, Ian H. de Boer,, Sc.D.,, M.D.。

    M.D.,, M.D.,, 在一项双盲试验中,,伴糖尿病肾病, after 3 years plus a 2-month washout period. Secondary outcomes included the decrease in the iohexol-based GFR per year and the urinary albumin excretion rate after washout. Safety was also assessed. Results A total of 267 patients were assigned to receive allopurinol and 263 to receive placebo. The mean age was 51.1 years, M.D.,该成果发表在2020年6月25日出版的《新英格兰医学杂志》上。

    0 to 80) higher with allopurinol than with placebo. The frequency of serious adverse events was similar in the two groups. Conclusions We found no evidence of clinically meaningful benefits of serum urate reduction with allopurinol on kidney outcomes among patients with type 1 diabetes and early-to-moderate diabetic kidney disease. DOI: 10.1056/NEJMoa1916624 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa1916624 期刊信息

  • 相关新闻:
最新新闻
热门新闻

中国健康世界网 All Rights Reserved 赣ICP备06006962号 邮箱:sheng6665588@gmail.com